Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2023-12-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings Classification · 95% confidence The document is an announcement from 3D Medicines Inc. regarding a change of the principal place of business in Hong Kong. It is a brief notice about an operational detail change, specifically the address of the company's principal place of business. There is no financial data, no discussion of management changes beyond the address, no voting results, no report publication, and no regulatory certification. The content is a straightforward corporate announcement about a business location change. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-27 English
INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS
Legal Proceedings Report Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules and Inside Information Provisions, concerning arbitration proceedings related to a licensing agreement dispute. It does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (3607 characters) and serves to inform shareholders and the public about a legal matter and the company's stance. It is not a full audit report, annual report, or earnings release. It is also not a certification or officer attestation. Given the nature of the content—legal dispute update—and the absence of detailed financial or operational data, the most appropriate classification is Legal Proceedings Report (LTR).
2023-12-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 30 November 2023. It details movements in authorized and issued shares, share options, and confirms compliance with listing rules. The document is regulatory in nature, providing updates on share capital and securities movements rather than financial performance or management commentary. It does not contain financial statements, earnings data, or detailed management discussion. It is not an announcement of voting results, nor a report on board changes or legal proceedings. The document fits the category of a regulatory filing as it is a compliance report submitted to the exchange under listing rules, providing required disclosures about share capital and securities movements.
2023-12-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 31 October 2023. It details movements in authorized and issued shares, share options, and confirms compliance with listing rules. The document is regulatory in nature, reporting share capital and share issuance movements, but it is not a financial report, earnings release, or management discussion. It is a regulatory filing reporting share capital movements and confirmations to the exchange, fitting the category of Regulatory Filings (RNS).
2023-11-03 English
VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3D Medicines Inc. regarding FDA approval to proceed with a global Phase III clinical trial for a cancer treatment drug. It provides updates on clinical trial progress, sales figures, and recent study results. The document is relatively short (4280 characters) and does not contain detailed financial statements or comprehensive financial performance data. It is an update on business development and regulatory progress rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation or a call transcript. The content is primarily a business development announcement related to clinical trial approval and progress. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2023-10-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, share options, and confirmations related to securities issued by 3D Medicines Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital movements and confirmations rather than financial performance, management changes, or earnings. It is a regulatory compliance filing related to share capital and securities movements, not a full financial report or announcement of voting results. Given the detailed nature and regulatory context, but not fitting into other specific categories like share issue announcements or director dealings, it best fits under Regulatory Filings (RNS) as a general regulatory compliance document.
2023-10-05 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.